A carregar cotações...
Previsão
Não temos dados de analistas para esta empresa.
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
CVR Energy misses Q1 2026 forecasts significantly and reports large net loss
CVR Energy reported Q1 2026 EPS of -1.24 USD, well below the expected -0.38 USD, while revenue of 1.98 billion USD exceeded estimates. The company recorded a consolidated net loss of 160 million USD and adjusted EBITDA of 37 million USD. Results were hurt by unrealized losses on derivative transactions and high RIN prices; the stock fell 1.58% in premarket trading. For Q2 2026 CVR expects throughput of 200,000–215,000 bpd and direct operating costs of 110–120 million USD; strategic adjustments to the crude slate are intended to improve margins. » Mais em de.investing.com
CVR Energy hits 52-week high and offers high dividend yield
CVR Energy’s stock rose to $33.25, marking a 52-week high and bringing market capitalization to about $3.33 billion. The yield is 11.49% and the company has paid dividends for 12 consecutive years. Despite a strong price gain of 39.4% over the past year (58.45% in six months), CVR reported an adjusted loss per share of $0.23 in Q2/2025 (expectation: -$0.06), but beat revenue expectations with $1.76 billion. Analyst notes indicate the stock may be trading above its fair value; gross profit margin remained weak at 1.63%. » Mais em de.investing.com
CVR Energy reaches 52-week high at 32.67 USD
CVR Energy’s stock rose to a 52-week high of 32.67 USD and has gained 70.7% over the past six months; year-to-date the increase is 49.4%. InvestingPro cites a dividend yield of 11.35% and notes 12 consecutive years of dividend payments, but considers the stock to be above its fair value. For Q2 2025 the company reported an adjusted loss per share of 0.23 USD (expectation: -0.06 USD) on revenue of 1.76 billion USD (expectation: 1.68 billion USD), after which the stock fell sharply in after-hours trading. » Mais em de.investing.com
CVRx increases revenue but misses earnings forecast in second quarter 2025
CVRx grew its revenue by 15% to $13.6 million in the second quarter of 2025, surpassing expectations, but reported a higher net loss of $0.57 per share compared to the forecast of $0.52. The stock saw a slight decline as profitability remains a challenge. The company is maintaining its full-year revenue guidance and is focusing on expanding in the US market and strengthening its sales team. » Mais em de.investing.com
CVRx receives continued Medicare reimbursement for Barostim but lowers revenue forecast
The Centers for Medicare and Medicaid Services propose to continue reimbursing CVRx's Barostim implantation procedure at around $45,000. Despite this positive regulatory development, CVRx missed revenue expectations in the first quarter and lowered its annual forecast, citing sales challenges. Analysts downgraded the stock due to ongoing uncertainties and volatile revenues. » Mais em de.investing.com
Dados financeiros da empresa
| (EUR) | 2021 | YoY |
|---|---|---|
| Receitas | 0 | - |
| Ganho bruto | -215,45 | 7,54% |
| Ganho líquido | -1,58 mi | 1.012,76% |
| EBITDA | -602,63 mil | 1.587,74% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 976,31 |
Número de ações | 107,2 mi |
Máximo/mínimo de 52 semanas | € 0,0000091 - € 0,0000009 |
| Dividendos | Não |
Beta | 1,82 |
PER (PE Ratio) | 0,00 |
PEG (PEG Ratio) | 0,00 |
P/VC (PB Ratio) | 0,00 |
P/V (PS Ratio) | 0,00 |
Perfil da empresa
A CVR Medical Corp., uma empresa do setor da saúde, dedica-se à investigação e desenvolvimento de tecnologia de análise de ondas sonoras subsónicas, infrassónicas e de baixa frequência para o setor da saúde. A empresa disponibiliza o dispositivo de análise de estenose carotídea, uma ferramenta de diagnóstico para detetar e medir a estenose arterial carotídea. Oferece os seus produtos a doentes, pagadores e prestadores de cuidados de saúde. A CVR Medical Corp. foi constituída em 1980 e tem sede em North Vancouver, Canadá.
| Nome | CVR Medical |
| CEO | Darren Day |
| Sede | North Vancouver,
bc Canadá |
| Site | |
| Entrada em bolsa | 02/11/2016 |
| Colaboradores | 3 |
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
Pnk | CRRVF |
London | 0UMW.L |
München | B3BN.MU |